Patients présentant un mélanome acro-lentigineux inclus dans la base nationale RIC-Mel
Émilie Varey(Inserm), Brigitte Dréno(Inserm), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), S. Dalac‐Rat(Centre Hospitalier du Mans), A. Dupuy(Hôpital Pontchaillou), Henri Montaudié(Hôpital l'Archet), E. Maubec(Délégation Paris 7), F. Skowron, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), B. Guillot(Université de Montpellier), P. Combemale(Centre Léon Bérard), Nicolás Meyer(Université Toulouse III - Paul Sabatier), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, Amir Khammari(Inserm), B. Crickx(Hôpital Bichat-Claude-Bernard), P. Celérier(Roche (France))
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k